[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-and-malignant-plasma-cell-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-and-malignant-plasma-cell-neoplasms":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,82,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100617536","phase-2-68ga-bcma-petct-in-multiple-myeloma-100617536",false,"NCT07319897","68Ga-BCMA PET\u002FCT in Multiple Myeloma","A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET\u002FCT for Targeting BCMA Expression in Multiple Myeloma.","Inclusion Criteria:\n\n* patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up\u002Fre-evaluation for disease monitoring or relapse;\n* patients with confirmed symptomatic MM;\n* ability to understand and voluntarily sign written informed consent;\n* ability to comply with study procedures;\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n\nExclusion Criteria:\n\n* pregnancy or lactation;\n* inability to comprehend study procedures or cooperate with protocol requirements;\n* any other condition judged by the investigator to potentially interfere with study participation.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography\u002Fcomputed tomography (PET\u002FCT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.",[29,30,31],"Multiple Myeloma","Multiple Myeloma and Malignant Plasma Cell Neoplasms","Multiple Myeloma and Plasma Cell Neoplasm",[33,34,35,36,37],"multiple myeloma","bcma","PET\u002FCT","diagnosis","multicenter","RECRUITING","2026-06-16",{"date":41,"type":42},"2026-06-22","ACTUAL",{"date":44,"type":42},"2025-12-25",{"date":46,"type":22},"2027-12-30",{"name":48,"class":49},"Peking University First Hospital","OTHER",5,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100620202","multiple-myeloma-extramedulary-disease-samples-ffpe-100620202","NCT07354555","Multiple Myeloma Extramedulary Disease Samples FFPE","Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma Extramedulary Disease","MMExFFPE","Inclusion Criteria:\n\n* Adult patients with histologically confirmed extramedullary myeloma (excluding plasmacytoma).\n* Availability of a representative FFPE block from a surgical specimen.\n* Diagnosis established within the past 10 years.\n* Availability of associated clinical and follow-up data.\n\nExclusion Criteria:\n\n* Patients with plasmacytoma only.\n* Insufficient or non-representative FFPE material.\n* Missing key diagnostic or clinical data.",{"count":60,"type":22},15,"OBSERVATIONAL","This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.\n\nNo intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.",[64,30],"Multiple Myeloma Survival Outcome",[66,67,68,69],"Myeloma","Extramedullary disease","histopathology","biomarker","NOT_YET_RECRUITING","2026-03-19",{"date":73,"type":42},"2026-03-20",{"date":75,"type":22},"2026-06-05",{"date":77,"type":22},"2026-10-01",{"name":79,"class":80},"BIWAKO","INDUSTRY",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":81},"100630060","multiple-myeloma-t4-14-ffpe-samples-100630060","NCT07482761","Multiple Myeloma t(4 ;14) FFPE Samples","Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma With t(4-14) and Relapse","MM-t4-14-FFPE","Inclusion Criteria:\n\n* Adult patients with histologically confirmed myeloma with a t(4;14) translocation\n* Availability of a representative FFPE block from a surgical specimen.\n* Diagnosis established within the past 10 years.\n* Availability of associated clinical and follow-up data.\n\nExclusion Criteria:\n\n* Bone lesions samples\n* Insufficient or non-representative FFPE material.\n* Missing key diagnostic or clinical data.",{"count":91,"type":22},20,"This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.\n\nNo intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.",[30],"2026-03-14",{"date":71,"type":42},{"date":97,"type":22},"2026-07-05",{"date":99,"type":22},"2027-06-01",{"name":79,"class":80},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100571197","early-phase-1-a-molecular-probe-targeting-bcma-for-the-clinical-diagnosis-of-multiple-myeloma-100571197","NCT06717113","A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma","Clinical PET Imaging Evaluation of 68Ga-BC1 Probe in Multiple Myeloma","Inclusion Criteria:\n\n* Suspected multiple myeloma patients scheduled for bone marrow aspiration or tissue biopsy within the past 3 months; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination.\n* Diagnosed symptomatic multiple myeloma patients; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination.\n\nExclusion Criteria:\n\n* Pregnant women; individuals unable to understand the examination process or who are unable to cooperate.",{"count":109,"type":22},50,[111],"EARLY_PHASE1","Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.",[30],[33,115,116],"molecular probe","Immuno-PET","2025-06-03",{"date":119,"type":42},"2025-06-06",{"date":121,"type":42},"2025-04-15",{"date":123,"type":22},"2028-12",{"name":48,"class":49},2]